Accelerated fibrin clot degradation is associated with arterial thromboembolism in patients following venous thrombosis: a cohort study.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
26 10 2021
26 10 2021
Historique:
received:
19
02
2021
accepted:
24
09
2021
entrez:
27
10
2021
pubmed:
28
10
2021
medline:
1
2
2022
Statut:
epublish
Résumé
Several lines of evidence have suggested that patients following venous thromboembolism (VTE) are at higher risk of arterial thromboembolism (ATE). Prothrombotic fibrin clot characteristics were reported in individuals with cardiovascular risk factors. We investigated whether specific fibrin clot properties measured after 3-4 months of anticoagulation characterize VTE patients with subsequent ATE. We enrolled 320 patients following VTE aged below 70 years (median age, 46). Ten patients were lost to follow-up. ATE occurred in 21 individuals after a median 54 (31-68) months during a follow-up of 87.5 months (incidence 0.94%; 95% confidence interval [CI], 0.59-1.4 per patient-year). Patients with ATE had faster fibrin clot degradation, reflected by maximum rate of D-dimer increase during plasma clot lysis induced by tissue-type plasminogen activator (D-D
Identifiants
pubmed: 34702844
doi: 10.1038/s41598-021-00411-6
pii: 10.1038/s41598-021-00411-6
pmc: PMC8548328
doi:
Substances chimiques
Fibrin Fibrinogen Degradation Products
0
fibrin fragment D
0
Types de publication
Clinical Trial
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
21003Informations de copyright
© 2021. The Author(s).
Références
Heit, J. A., Spencer, F. A. & White, R. H. The epidemiology of venous thromboembolism. J. Thromb. Thrombolysis. 41, 3–14 (2016).
pubmed: 26780736
pmcid: 4715842
doi: 10.1007/s11239-015-1311-6
Lowe, G. D. O. Common risk factors for both arterial and venous thrombosis. Br. J. Haematol. 140, 488–495 (2008).
pubmed: 18275426
doi: 10.1111/j.1365-2141.2007.06973.x
Prandoni, P. Venous and arterial thrombosis: two aspects of the same disease?. Eur. J. Intern. Med. 20, 660–661 (2009).
pubmed: 19782933
doi: 10.1016/j.ejim.2009.02.001
Becattini, C., Vedovati, M. C., Ageno, W., Dentali, F. & Agnelli, G. Incidence of arterial cardiovascular events after venous thromboembolism: a systematic review and a meta-analysis. J. Thromb. Haemost. 8, 891–897 (2010).
pubmed: 20095999
doi: 10.1111/j.1538-7836.2010.03777.x
Prandoni, P. et al. Venous thromboembolism and the risk of subsequent symptomatic atherosclerosis. J. Thromb. Haemost. 4, 1891–1896 (2006).
pubmed: 16961597
doi: 10.1111/j.1538-7836.2006.02058.x
Sørensen, H. T., Horvath-Puho, E., Pedersen, L., Baron, J. A. & Prandoni, P. Venous thromboembolism and subsequent hospitalisation due to acute arterial cardiovascular events: a 20-year cohort study. Lancet 370, 1773–1779 (2007).
pubmed: 18037081
doi: 10.1016/S0140-6736(07)61745-0
Spencer, F. A., Ginsberg, J. S., Chong, A. & Alter, D. A. The relationship between unprovoked venous thromboembolism, age, and acute myocardial infarction. J. Thromb. Haemost. 6, 1507–1513 (2008).
pubmed: 18624983
doi: 10.1111/j.1538-7836.2008.03062.x
Prandoni, P. et al. An association between atherosclerosis and venous thrombosis. N. Engl. J. Med. 348, 1435–1441 (2003).
pubmed: 12686699
doi: 10.1056/NEJMoa022157
Schulman, S. et al. Post-thrombotic syndrome, recurrence, and death 10 years after the first episode of venous thromboembolism treated with warfarin for 6 weeks or 6 months. J. Thromb. Haemost. 4, 734–742 (2006).
pubmed: 16634738
doi: 10.1111/j.1538-7836.2006.01795.x
Anderson, F. A. Jr. & Spencer, F. A. Risk factors for venous thromboembolism. Circulation 107, I9–I16 (2003).
pubmed: 12814980
doi: 10.1161/01.CIR.0000078469.07362.E6
Greenland, P. et al. American College of Cardiology Foundation; American Heart Association. 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J. Am. Coll. Cardiol. 56, e50–e103 (2010).
pubmed: 21144964
doi: 10.1016/j.jacc.2010.09.001
Previtali, E., Bucciarelli, P., Passamonti, S. M. & Martinelli, I. Risk factors for venous and arterial thrombosis. Blood Transfus. 9, 120–138 (2011).
pubmed: 21084000
pmcid: 3096855
Lóczi, L., Kappelmayer, J., Tarr, T. & Bagoly, Z. Antiphospholipid syndrome and the risk of myocardial infarction: Current evidence and uncertainties. Kardiol. Pol. 78, 6–14 (2020).
pubmed: 31808421
doi: 10.33963/KP.15090
Mahmoodi, B. K., Brouwer, J. L., Veeger, N. J. & van der Meer, J. Hereditary deficiency of protein C or protein S confers increased risk of arterial thromboembolic events at a young age: Results from a large family cohort study. Circulation 118, 1659–1667 (2008).
pubmed: 18824642
doi: 10.1161/CIRCULATIONAHA.108.780759
Reynaud, Q. et al. Risk of venous and arterial thrombosis according to type of antiphospholipid antibodies in adults without systemic lupus erythematosus: a systematic review and meta-analysis. Autoimmun. Rev. 13, 595–608 (2014).
pubmed: 24418303
doi: 10.1016/j.autrev.2013.11.004
Lowe, G. D. O. Arterial disease and venous thrombosis: Are they related, and if so, what should we do about it?. J. Thromb. Haemost. 4, 1882–1885 (2006).
pubmed: 16848865
doi: 10.1111/j.1538-7836.2006.02130.x
Gradolí, J., Vidal, V., Brady, A. J. & Facila, L. Anticoagulation in patients with ischaemic heart disease and peripheral arterial disease: clinical implications of COMPASS study. Eur. Cardiol. 13, 115–118 (2018).
pubmed: 30697356
pmcid: 6331781
doi: 10.15420/ecr.2018.12.2
Undas, A. Fibrin clot properties and their modulation in thrombotic disorders. Thromb. Haemost. 112, 32–42 (2014).
pubmed: 24671700
doi: 10.1160/TH14-01-0032
Zabczyk, M., Plens, K., Wojtowicz, W. & Undas, A. Prothrombotic fibrin clot phenotype is associated with recurrent pulmonary embolism after discontinuation of anticoagulant therapy. Arterioscler. Thromb. Vasc. Biol. 37, 365–373 (2017).
pubmed: 28062504
doi: 10.1161/ATVBAHA.116.308253
Cieslik, J., Mrozinska, S., Broniatowska, E. & Undas, A. Altered plasma clot properties increase the risk of recurrent deep vein thrombosis: a cohort study. Blood 131, 797–807 (2018).
pubmed: 29242187
doi: 10.1182/blood-2017-07-798306
Undas, A. & Casini, A. Congenital structural and functional fibrinogen disorders: a primer for internists. Pol. Arch. Intern. Med. 129, 913–920 (2019).
pubmed: 31797863
Undas, A. & Ariëns, R. A. S. Fibrin clot structure and function: a role in the pathophysiology of arterial and venous thromboembolic diseases. Arterioscler. Thromb. Vasc. Biol. 31, e88–e99 (2011).
pubmed: 21836064
doi: 10.1161/ATVBAHA.111.230631
Undas, A. et al. Altered fibrin clot structure/function in patients with cryptogenic ischemic stroke. Stroke 40, 1499–1501 (2009).
pubmed: 19246700
doi: 10.1161/STROKEAHA.108.532812
Mills, J. D., Ariëns, R. A. S., Mansfield, M. W. & Grant, P. J. Altered fibrin clot structure in the healthy relatives of patients with premature coronary artery disease. Circulation 106, 1938–1942 (2002).
pubmed: 12370216
doi: 10.1161/01.CIR.0000033221.73082.06
Barua, R. S. et al. Effects of cigarette smoke exposure on clot dynamics and fibrin structure: an ex vivo investigation. Arterioscler. Thromb. Vasc. Biol. 30, 75–79 (2010).
pubmed: 19815816
doi: 10.1161/ATVBAHA.109.195024
Vilar, R., Fish, R. J., Casini, A. & Neerman-Arbez, M. Fibrin(ogen) in human disease: both friend and foe. Haematologica 105, 284–296 (2020).
pubmed: 31949010
pmcid: 7012490
doi: 10.3324/haematol.2019.236901
Seehaus, S. et al. Hypercoagulability inhibits monocyte transendothelial migration through protease-activated receptor-1-, phospholipase-Cbeta-, phosphoinositide 3-kinase-, and nitric oxide-dependent signaling in monocytes and promotes plaque stability. Circulation 120, 774–784 (2009).
pubmed: 19687358
doi: 10.1161/CIRCULATIONAHA.109.849539
Collet, J. P. et al. Abnormal fibrin clot architecture in nephrotic patients is related to hypofibrinolysis: influence of plasma biochemical modifications: a possible mechanism for the high thrombotic tendency?. Thromb. Haemost. 82, 1482–1489 (1999).
doi: 10.1055/s-0037-1614859
Sane, D. C. et al. The Thrombolysis and Angioplasty in Myocardial Infarction Study Group Racial differences in responses to thrombolytic therapy with recombinant tissue-type plasminogen activator Increased fibrin(ogen)olysis in blacks. Circulation 83, 170–175 (1991).
pubmed: 1898641
doi: 10.1161/01.CIR.83.1.170
Undas, A., Celinska-Löwenhoff, M., Löwenhoff, T. & Szczeklik, A. Statins, fenofibrate, and quinapril increase clot permeability and enhance fibrinolysis in patients with coronary artery disease. J. Thromb. Haemost. 4, 1029–1036 (2006).
pubmed: 16689755
doi: 10.1111/j.1538-7836.2006.01882.x
Undas, A. et al. Altered plasma fibrin clot properties are associated with in-stent thrombosis. Arterioscler. Thromb. Vasc. Biol. 30, 276–282 (2010).
pubmed: 19910643
doi: 10.1161/ATVBAHA.109.194936
Karpińska, I. A., Nowakowski, T., Wypasek, E., Plens, K. & Undas, A. A prothrombotic state and denser clot formation in patients following acute limb ischemia of unknown cause. Thromb. Res. 187, 32–38 (2020).
pubmed: 31951936
doi: 10.1016/j.thromres.2020.01.008
Siudut, J., Natorska, J., Son, M., Plens, K. & Undas, A. Increased levels of histidine-rich glycoprotein are associated with the development of post-thrombotic syndrome. Sci. Rep. 10, 14419 (2020).
pubmed: 32879351
pmcid: 7468120
doi: 10.1038/s41598-020-71437-5
Siudut, J., Iwaniec, T., Plens, K., Pieters, M. & Undas, A. Determinants of plasma fibrin clot lysis measured using three different assays in healthy subjects. Thromb. Res. 197, 1–7 (2021).
pubmed: 33157491
doi: 10.1016/j.thromres.2020.10.014
Corban, M. T. et al. Elevated levels of serum fibrin and fibrinogen degradation products are independent predictors of larger coronary plaques and greater plaque necrotic core. Circ. J. 80, 931–937 (2016).
pubmed: 26911453
pmcid: 4857724
doi: 10.1253/circj.CJ-15-0768
Luyendyk, J. P., Schoenecker, J. G. & Flick, M. J. The multifaceted role of fibrinogen in tissue injury and inflammation. Blood 133, 511–520 (2019).
pubmed: 30523120
pmcid: 6367649
doi: 10.1182/blood-2018-07-818211
Qi, J. & Kreutzer, D. L. Fibrin activation of vascular endothelial cells. Induction of IL-8 expression. J. Immunol. 155, 867–876 (1995).
pubmed: 7608564
doi: 10.4049/jimmunol.155.2.867
Harley, S. L., Sturge, J. & Powell, J. T. Regulation by fibrinogen and its products of intercellular adhesion molecule-1 expression in human saphenous vein endothelial cells. Arterioscler. Thromb. Vasc. Biol. 20, 652–658 (2000).
pubmed: 10712387
doi: 10.1161/01.ATV.20.3.652
Spronk, H. M. H., van der Voort, D. & Ten Cate, H. Blood coagulation and the risk of atherothrombosis: a complex relationship. Thromb. J. 2, 12 (2004).
pubmed: 15574198
pmcid: 538274
doi: 10.1186/1477-9560-2-12
Borissoff, J. I., Spronk, H. M. H., Heeneman, S. & ten Cate, H. Is thrombin a key player in the “coagulation-atherogenesis” maze?. Cardiovasc. Res. 82, 392–403 (2009).
pubmed: 19228706
doi: 10.1093/cvr/cvp066
Borissoff, J. I., Spronk, H. M. H. & ten Cate, H. The hemostatic system as a modulator of atherosclerosis. N. Engl. J. Med. 364, 1746–1760 (2011).
pubmed: 21542745
doi: 10.1056/NEJMra1011670
Borissoff, J. I. et al. Early atherosclerosis exhibits an enhanced procoagulant state. Circulation 122, 821–830 (2010).
pubmed: 20697022
doi: 10.1161/CIRCULATIONAHA.109.907121
Kalz, J., ten Cate, H. & Spronk, H. M. Thrombin generation and atherosclerosis. J. Thromb. Thrombolysis. 37, 45–55 (2014).
pubmed: 24241912
doi: 10.1007/s11239-013-1026-5
Golemi, I. et al. Registro Informatizado de Enfermedad Tromboembólica Investigators. Incidence of major adverse cardiovascular events among patients with provoked and unprovoked venous thromboembolism: Findings from the Registro Informatizado de Enfermedad Tromboembólica Registry. J. Vasc. Surg. Venous Lymphat. Disord. 8, 353–359 (2020).
pubmed: 31784355
doi: 10.1016/j.jvsv.2019.03.011
Stec, J. J. et al. Association of fibrinogen with cardiovascular risk factors and cardiovascular disease in the Framingham Offspring Population. Circulation 102, 1634–1638 (2000).
pubmed: 11015340
doi: 10.1161/01.CIR.102.14.1634
Emerging Risk Factors Collaboration, Kaptoge, S., et al. C-reactive protein, fibrinogen, and cardiovascular disease prediction. N Engl J Med. 367, 1310–1320 (2012).
Kearon, C. et al. Antithrombotic therapy for VTE disease: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141, e419S-e496S (2012).
pubmed: 22315268
pmcid: 3278049
doi: 10.1378/chest.11-2301
Sacco, R.L. et al., American Heart Association Stroke Council, Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular Radiology and Intervention; Council on Cardiovascular and Stroke Nursing; Council on Epidemiology and Prevention; Council on Peripheral Vascular Disease; Council on Nutrition, Physical Activity and Metabolism. An updated definition of stroke for the 21st century: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 44, 2064–2089 (2013).
Ibánez, B. et al., ESC Scientific Document Group. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the task force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 39, 119–177 (2018).
Hirsch, A.T. et al., American Association for Vascular Surgery; Society for Vascular Surgery; Society for Cardiovascular Angiography and Interventions; Society for Vascular Medicine and Biology; Society of Interventional Radiology; ACC/AHA Task Force on Practice Guidelines Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease; American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; Vascular Disease Foundation. ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. Circulation. 113, e463-e654 (2006).
Undas, A. et al. Altered fibrin clot structure/function in patients with idiopathic venous thromboembolism and in their relatives. Blood 114, 4272–4278 (2009).
pubmed: 19690336
doi: 10.1182/blood-2009-05-222380
Kupis, R. W., Goldman-Mazur, S., Polak, M., Ząbczyk, M. & Undas, A. Faster fibrin clot degradation characterizes patients with central pulmonary embolism at a low risk of recurrent peripheral embolism. Sci. Rep. 9, 72 (2019).
pubmed: 30635605
pmcid: 6329786
doi: 10.1038/s41598-018-37114-4
R Core Team (2018). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. Available online at https://www.R-project.org/ .
Erdfelder, E., Faul, F. & Buchner, A. GPOWER: A general power analysis program. Behav. Res. Methods Instrum. Comput. 28, 1–11 (1996).
doi: 10.3758/BF03203630